Cytokinetics, Incorporated ($CYTK) Stock Forecast: Up 5.1% Today

What is Cytokinetics, Incorporated?

Cytokinetics (CYTK) is a biopharmaceutical company focused on developing muscle activators as potential treatments for debilitating diseases. The company recently received regulatory approval for Myqorzo, a treatment for obstructive hypertrophic cardiomyopathy, which has generated significant market interest.

Why is Cytokinetics, Incorporated going up?

CYTK stock is up 5.1% on Mar 17, 2026 17:15

• An increased price target and positive outlook on Cytokinetics have fueled investor optimism, leading to a bullish market movement.
• A substantial purchase of CYTK shares indicates growing confidence in the company's future prospects.
• Despite insider selling activities by executives like Andrew Callos, the overall market sentiment remains positive due to the potential growth opportunities presented by Myqorzo and upcoming data releases.
• The recent presentation of new clinical data on MYQORZO has provided further validation of its efficacy, potentially driving increased investor interest and contributing to the bullish trend in CYTK's stock price.

CYTK Price Chart

CYTK Technical Analysis

CYTK News

JPMorgan Boosts Price Target on Cytokinetics (CYTK) Amid Positive Outlook

JPMorgan has raised its price target for Cytokinetics (CYTK) to $75 and maintained an Overweight rating, adding it to its Analyst Focus List due to its potential as a significant growth opportunity. This positive re-evaluation follows regulatory approval for Myqorzo, a treatment for obstructive hypertrophic cardiomyopathy, and the anticipation of future data releases which could further enhance its market success. Despite promising developments, Cytokinetics faces financial challenges including negative revenue growth, significant losses, and a distress zone Altman Z-Score.

https://www.gurufocus.com/news/8717573/jpmorgan-boosts-price-target-on-cytokinetics-cytk-amid-positive-outlook

Granahan Investment Management LLC Purchases Shares of 53,550 Cytokinetics, Incorporated $CYTK

Granahan Investment Management LLC recently acquired 53,550 shares of Cytokinetics, Inc. (NASDAQ:CYTK) for approximately $2.94 million in the third quarter. Other institutional investors have also adjusted their holdings, with several analysts maintaining "Buy" or "Outperform" ratings and setting price targets up to $136. Insiders, however, have sold a significant number of shares, while the company's stock trades at $60.83 with a market cap of $7.49 billion.

https://www.marketbeat.com/instant-alerts/filing-granahan-investment-management-llc-purchases-shares-of-53550-cytokinetics-incorporated-cytk-2026-03-17/

Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation

Cytokinetics presented new clinical data on MYQORZO for obstructive hypertrophic cardiomyopathy, covering exercise capacity, effectiveness across hypertension subgroups, and safety during treatment interruption. The drug is a recently approved oHCM therapy, and the new analyses provide further detail on its performance. The company's shares are trading at $60.83, with analysts seeing potential value at $91.61, and Simply Wall St's model views the stock as undervalued despite recent share price decline.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-myqorzo-data-sheds-light-on-ohcm-outlook-and-va/amp

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK)

Andrew Callos, Executive Vice President, Chief Commercial Officer at Cytokinetics Inc, sold 1,709 shares of the company on March 16, 2026. This transaction follows a pattern of 70 insider sells and no insider buys at Cytokinetics Inc over the past year. The stock is currently trading at $61.03, which, compared to its GF Value of $208.58, suggests it might be a "Possible Value Trap."

https://www.gurufocus.com/news/8716706/insider-sell-andrew-callos-sells-shares-of-cytokinetics-inc-cytk

Cytokinetics (NASDAQ:CYTK) EVP Sells $104,300.27 in Stock

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos sold 1,709 shares of company stock for $104,300.27, reducing his stake by 3.57% to 46,149 shares. This sale is part of several recent transactions by Callos totaling over $3.7 million. The company recently reported Q1 EPS of -$1.50, missing estimates, but revenue of $17.76 million significantly beat expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $89.

https://www.marketbeat.com/instant-alerts/cytokinetics-nasdaqcytk-evp-sells-10430027-in-stock-2026-03-16/

Trending Today

Gold ($XAU) Commodity Forecast: Down 5.3% Today

Silver ($XAG) Commodity Forecast: Down 5.2% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.6% Today

Cytokinetics, Incorporated Price History

31.11.2025 - CYTK Stock was up 5.3%

• The positive market sentiment surrounding CYTK's bullish movement may have outweighed concerns related to insider selling by the Executive Vice President and Chief Commercial Officer, Andrew Callos.
• Despite an ongoing securities investigation, analysts continue to uphold a "Moderate Buy" rating for CYTK, accompanied by a favorable target price, potentially instilling confidence in investors.
• It is possible that investors interpret the insider selling as routine profit-taking or strategic portfolio adjustments by company executives rather than a cause for alarm about the company's fundamentals.
• Generally, the market appears to have discounted the investigation news and shifted its focus towards the growth opportunities presented by the company, driving the bullish movement in CYTK.

07.00.2026 - CYTK Stock was up 6.3%

• The rise in CYTK's stock price is possibly linked to the excitement surrounding the imminent presentation at the J.P. Morgan Healthcare Conference, where the company's President and CEO will present advancements in treatments for cardiac muscle dysfunction.
• Despite initial concerns raised by the EVP's recent insider selling, investors appear more focused on CYTK's drug pipeline potential, especially following the FDA approval of MYQORZO and the increased price targets from analyst firms.
• Investor confidence in CYTK's long-term growth potential is likely buoyed by the company's diversification efforts and the anticipation of the MYQORZO launch later this month.
• The varied performance of CYTK shares over the past month has seemingly been overshadowed by the positive market sentiment towards the company's valuation, driven by progress in its late-stage pipeline and the market's confidence in its future growth prospects.

10.02.2026 - CYTK Stock was up 4.7%

• A Neutral rating was maintained on CYTK by UBS, with a raised price target linked to a positive outlook for the nHCM program, potentially influencing the bullish movement.
• An investigation into possible corporate misconduct could have caused initial market uncertainty, but positive developments overshadowed its impact.
• Participation in the Leerink Partners Global Biopharma Conference allowed CYTK to highlight growth strategies and upcoming milestones, potentially enhancing investor confidence.
• Despite an ESOP shelf offering and Q4 losses, the commercialization of aficamten and notable investments from individuals like Knott David M Jr may have boosted investor optimism, contributing to the bullish market movement.

25.01.2026 - CYTK Stock was down 7.8%

• Despite recent regulatory approvals, CYTK witnessed a downward trend in trading today.
• Profit-taking actions after a notable 41% increase in the stock price over the past year might be influencing the current bearish movement.
• Concerns about the Price-to-Book ratio of 15.94x, surpassing industry norms, could be contributing to worries about the stock potentially being overvalued.
• Uncertainties surrounding future revenue growth and risk factors, as discussed in contrasting narratives, may be prompting investor hesitancy and impacting CYTK's stock price negatively despite its favorable market outlook.

18.11.2025 - CYTK Stock was up 5.3%

• Approval of Myqorzo in China for treating obstructive hypertrophic cardiomyopathy has boosted investor confidence in Cytokinetics.
• A milestone payment triggered by China's National Medical Products Administration's approval, potential future milestone payments, and royalties have drawn positive attention to the company.
• Mirador Capital Partners LP increasing its stake signals growing investor interest and confidence in Cytokinetics' future, despite recent insider selling.
• Ongoing regulatory reviews in the U.S. and Europe, with critical decisions expected in late 2025 and Q1 2026, are anticipated catalysts for further market movement as investors await these essential milestones.

26.01.2026 - CYTK Stock was down 5.2%

• Cytokinetics (CYTK) reported a Q4 loss wider than anticipated, raising concerns among investors about profitability. Despite surpassing revenue expectations, this financial setback has overshadowed the recent FDA nod for MyQorzo and the company's global expansion efforts.
• The discrepancy between optimistic analyst forecasts linked to future revenue growth and the current financial performance with high operating expenses and negative equity has fueled the stock's bearish trend.
• Despite a considerable stock price surge in the past year, the elevated Price-to-Book ratio compared to industry peers and uncertainties regarding future revenue indicators have led to varying assessments of its value. Some argue for substantial undervaluation, while others question the current price level.

17.02.2026 - CYTK Stock was up 5.1%

• An increased price target and positive outlook on Cytokinetics have fueled investor optimism, leading to a bullish market movement.
• A substantial purchase of CYTK shares indicates growing confidence in the company's future prospects.
• Despite insider selling activities by executives like Andrew Callos, the overall market sentiment remains positive due to the potential growth opportunities presented by Myqorzo and upcoming data releases.
• The recent presentation of new clinical data on MYQORZO has provided further validation of its efficacy, potentially driving increased investor interest and contributing to the bullish trend in CYTK's stock price.

23.11.2025 - CYTK Stock was down 7.9%

• Cytokinetics' Myqorzo was recently approved by the FDA for obstructive hypertrophic cardiomyopathy (oHCM) after 28 years, marking the company's first U.S. drug approval.
• Despite the positive FDA approval, concerns arose among investors due to the "black box" warning associated with Myqorzo, highlighting the risk of heart failure in certain patients.
• The news of an investigation into potential corporate misconduct at Cytokinetics by Bronstein, Gewirtz & Grossman, LLC may have contributed to the negative investor sentiment surrounding the stock.
• Additionally, the competitive pressure from Bristol Myers Squibb's successful drug Camzyos in the same market segment may have further impacted Cytokinetics' stock price.

06.00.2026 - CYTK Stock was up 5.1%

• The rise in CYTK stock today is linked to an upcoming presentation by the company's President and CEO at a significant industry conference, sparking investor interest and confidence.
• Despite initial concerns surrounding insider selling by the Executive Vice President, market sentiment appears to have improved following FDA approval of Cytokinetics' drug MYQORZO for obstructive hypertrophic cardiomyopathy. This approval has led to increased price targets from analyst groups.
• Investors may find comfort in the company's efforts to lessen reliance on a single product and the promise of its late-stage cardiology pipeline, likely contributing to the stock's positive momentum.
• While the stock has shown mixed performance in the past month, alongside long-term gains and company valuation assessments, it may present a buying opportunity for investors anticipating Cytokinetics' future growth prospects.

12.02.2026 - CYTK Stock was down 5.0%

• Despite maintaining an "Outperform" rating for CYTK, insider selling by EVP Fady Ibraham Malik and CEO Robert Blum might have signaled lack of confidence in the company's future prospects.
• The slight miss on quarterly EPS but significant beat on revenue estimates could have contributed to investor uncertainty and the subsequent bearish movement in the stock price.
• The valuation analysis post-analyst updates and the launch of Myqorzo, indicating the stock is undervalued by 21.5%, could have raised concerns about the company's growth potential and future earnings, impacting investor sentiment.
• The diverse price targets from analysts and the varying outlooks on the company's performance might have added to the market volatility and contributed to the bearish trend in CYTK's stock price.

05.01.2026 - CYTK Stock was down 5.0%

• The decline in CYTK stock today could be linked to an investigation into potential corporate misconduct, possibly sparking investor concerns and leading to a sell-off.
• Despite the positive news of Myqorzo's FDA approval and market outlook, uncertainties stemming from the investigation could have overshadowed the optimistic analyst projections and raised price target.
• Investor caution may be influenced by the ongoing legal scrutiny and its potential effects on the company's reputation and future opportunities, despite the positive outlook for CYTK's lead drug Aficamten and its growth potential in the HCM market.
• The contrasting views between positive analyst ratings and the legal investigation may have contributed to the volatile trading atmosphere surrounding CYTK stock, resulting in the observed downward trend today.

08.00.2026 - CYTK Stock was down 6.4%

• The bearish movement in CYTK's stock could be attributed to the significant insider selling by the Executive Vice President, Andrew Callos, which might have raised concerns among investors about the company's future prospects.
• Despite the insider selling, analysts maintain a "Moderate Buy" rating for Cytokinetics, indicating a potential disconnect between insider actions and market sentiment.
• The upcoming presentation by the President and CEO at the J.P. Morgan Healthcare Conference may have heightened investor scrutiny, leading to profit-taking and a bearish trend in the stock.
• Investors evaluating CYTK's valuation post recent momentum cooling and pipeline progress may have contributed to the bearish sentiment, as uncertainties around market appreciation of the company's drug pipeline potential linger.